Within the spectrum of fibrosing interstitial lung diseases (ILDs) is a subset of patients who
have inexorable progression of pulmonary fibrosis despite treatment, which is known as the …

Pirfenidone is an orally active small molecule that has been shown to inhibit the progression
of fibrosis in animal models and in patients with idiopathic pulmonary fibrosis. Although …

Prostaglandin E 2 (PGE 2 ) is commonly considered a potent proinflammatory mediator and
is involved in several inflammatory diseases. In the lung, as opposed to many other parts of …

Background Since 2009, IPF patients across Europe are recruited into the eurIPFreg, providing
epidemiological data and biomaterials for translational research. Methods The registry …

Idiopathic pulmonary fibrosis (IPF) is marked by a very disappointing survival rate and still
represents a clinical dilemma. According to the current pathogenic hypothesis, chronic …

Rationale: Nintedanib and pirfenidone slow the progression of idiopathic pulmonary fibrosis
(IPF), but the disease continues to progress. More data are needed on the safety and …

Transforming growth factor-β1 (TGF-β1) is known to induce the transition of human lung
fibroblasts to myofibroblasts, a primary event in the pathogenesis of idiopathic pulmonary fibrosis…

Objectives To explore the performance of the neutrophil‐to‐lymphocyte ratio ( NLR ), an index
of systemic inflammation that predicts prognosis of several diseases, in a cohort of elderly …

Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the
occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung …

Idiopathic pulmonary fibrosis (IPF) is a progressive fibroproliferative disease characterized
by an accumulation of fibroblasts and myofibroblasts in the alveolar wall. Even though the …